Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.
about
Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen.Hsp70 expression and induction as a readout for detection of immune modulatory components in food.Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinomaCD1d activation and blockade: a new antitumor strategyImmune surveillance of tumors.Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.Challenges and future perspectives of T cell immunotherapy in cancerThe Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population.The roles for cytokines in the generation and maintenance of regulatory T cells.The tumor-draining lymph node as an immune-privileged site.Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma.The impact of regulatory T cells on carcinogen-induced sarcogenesisThe role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.Therapeutic use of Aldara in chronic myeloid leukemia.Indoleamine 2,3-dioxygenase and tumor-induced toleranceOvercoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.Type I natural killer T cells suppress tumors caused by p53 loss in mice.Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer.Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearanceA reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.Unravelling the complexity of cancer-immune system interplay.Intestinal inflammation and colorectal cancer: a double-edged sword?IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors.Regulatory T cells in inflammatory bowel diseases and colorectal cancer.Heat shock proteins can be targets of regulatory T cells for therapeutic intervention in rheumatoid arthritis.HLA ligandome tumor antigen discovery for personalized vaccine approach.Immunotherapy for lung cancer: for whom the bell tolls?Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses.Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity.Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells.TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer.IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors.3-Methylcholanthrene-induced transforming growth factor-beta-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy.Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.
P2860
Q33280654-782386EE-E273-4774-A120-1518405F62F8Q33838876-5A6EFD91-5586-45AF-AF94-EC6B86A2CB6DQ33865610-730F2DB1-EA01-4397-90DE-D15C2DBD6FBCQ34257902-0653FE27-8EAB-456E-8AAA-B9AC12DD0EC3Q34579196-C4788028-E406-4716-9128-DE5463452146Q34610483-6F9A8720-06B2-4E9D-9753-305B79B14111Q35843507-04D428E0-5F0A-40BB-8B73-AE5A6F8DB74CQ35884237-1A30B571-265D-4EF0-A665-ACBAA20A9E02Q36499318-2317865F-B5C3-4599-B39F-4144AD9786FDQ36563513-20B7E056-82A0-4474-963B-756A6DFA4B8FQ36593753-6AE3E737-B16B-42D0-B20A-DB70E96CBCE8Q36608555-74522946-534C-41CC-99A4-EA32D67E061BQ36609617-44FCA4C0-F14F-4C35-A6E0-8151132FA649Q36652214-6D146476-27EE-46D9-A27B-1AB669C5BA31Q36718548-737BB0C8-01F2-47DF-823D-89F727D1BE37Q36809762-0FDBC5BE-B02B-4019-8750-D417731A40F3Q37017190-A0A6A7C1-47E6-49A5-B7A2-02AC11F435E5Q37262415-AE029EC4-9B22-438D-AE1D-F60B8304779CQ37280390-0B701147-57FC-42BD-A228-7140CF8779A6Q37440379-E4DC2DE2-2197-4E74-853F-FAA23F411682Q37729253-46EAD9A3-B434-464B-8E83-85B3EF5816F6Q37765590-D2C3465D-67A7-485D-AD9B-BE27716EBFEEQ37930988-42AE0752-46ED-4FB4-BE5E-6C20204D726AQ37937750-062594C3-485D-4434-85B2-ECF1B229AB10Q38060115-B7859ED0-8A41-4BA2-A830-FE1FB88890C4Q38122210-39933AA2-B1BD-4D9D-96AB-D1AC29E33711Q38148779-86E8BD3D-663A-4B61-A6BA-797CE2646302Q38367414-90FDABCE-2E89-4C84-950F-80A33096DDC8Q38979523-0EAF842E-499B-426E-A709-6FBCEAEB46D5Q39516758-4756D312-9719-4357-BFF4-D8DCA07FE3C4Q39870340-87F265F4-D5CF-4016-A53A-68DBEA1BB6A8Q39904256-39BFF097-22CC-4C94-A9C0-0AD559CAA0E4Q40347818-D14394F7-A4B7-452E-A76A-9F8FCE0A55B0Q41945018-01AD6013-DD24-4967-A831-BE17415207D0Q42242575-0B5488F9-08CF-4086-8921-4031552D217CQ43163965-574B17F5-5E88-4FB1-BBC2-08AEBA9CD9CEQ44851304-0A52C71B-90A6-4119-9BA8-F8395D1A026BQ46264501-079710EC-E1C4-43AB-891E-CCD68EF45B5EQ50909597-1012126B-47FE-4D3A-846E-81F4E9C9ACE0Q50912428-548EFBFA-DA5E-4EF4-B633-D2DBE6E72EF9
P2860
Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Accelerated chemically induced ...... ry T cells in wild-type hosts.
@ast
Accelerated chemically induced ...... ry T cells in wild-type hosts.
@en
type
label
Accelerated chemically induced ...... ry T cells in wild-type hosts.
@ast
Accelerated chemically induced ...... ry T cells in wild-type hosts.
@en
prefLabel
Accelerated chemically induced ...... ry T cells in wild-type hosts.
@ast
Accelerated chemically induced ...... ry T cells in wild-type hosts.
@en
P2093
P2860
P356
P1476
Accelerated chemically induced ...... ry T cells in wild-type hosts.
@en
P2093
Hiro Wakasugi
Hiroshi Shiku
Hiroyoshi Nishikawa
Isao Tawara
Kagemasa Kuribayashi
Kanako Saito
Linan Wang
Lloyd J Old
Masaru Taniguchi
Takuma Kato
P2860
P304
P356
10.1073/PNAS.0503852102
P407
P577
2005-06-16T00:00:00Z